Benzinga | Jun 2, 2021 08:43AM EDT

Morgan Stanley Maintains Overweight on Abbott Laboratories, Lowers Price Target to $126

Morgan Stanley analyst Cecilia Furlong maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $140 to $126.